Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia
Top Cited Papers
Open Access
- 12 April 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 65 (2), 183-190
- https://doi.org/10.1093/cid/cix317
Abstract
Recent trials suggest procalcitonin-based guidelines can reduce antibiotic use for respiratory infections. However, the accuracy of procalcitonin to discriminate between viral and bacterial pneumonia requires further dissection. We evaluated the association between serum procalcitonin concentration at hospital admission with pathogens detected in a multicenter prospective surveillance study of adults hospitalized with community-acquired pneumonia. Systematic pathogen testing included cultures, serology, urine antigen tests, and molecular detection. Accuracy of procalcitonin to discriminate between viral and bacterial pathogens was calculated. Among 1735 patients, pathogens were identified in 645 (37%), including 169 (10%) with typical bacteria, 67 (4%) with atypical bacteria, and 409 (24%) with viruses only. Median procalcitonin concentration was lower with viral pathogens (0.09 ng/mL; interquartile range [IQR], P = .05), and typical bacteria (2.5 ng/mL; IQR, 0.29–12.2 ng/mL; P < .01). Procalcitonin discriminated bacterial pathogens, including typical and atypical bacteria, from viral pathogens with an area under the receiver operating characteristic (ROC) curve of 0.73 (95% confidence interval [CI], .69–.77). A procalcitonin threshold of 0.1 ng/mL resulted in 80.9% (95% CI, 75.3%–85.7%) sensitivity and 51.6% (95% CI, 46.6%–56.5%) specificity for identification of any bacterial pathogen. Procalcitonin discriminated between typical bacteria and the combined group of viruses and atypical bacteria with an area under the ROC curve of 0.79 (95% CI, .75–.82). No procalcitonin threshold perfectly discriminated between viral and bacterial pathogens, but higher procalcitonin strongly correlated with increased probability of bacterial pathogens, particularly typical bacteria.Keywords
Funding Information
- National Institute on Aging (R01AG043471)
- National Institute of General Medical Sciences
- CDC (U18 IP000299, K23GM110469)
This publication has 32 references indexed in Scilit:
- Does Empiric Therapy for Atypical Pathogens Improve Outcomes for Patients with CAP?Infectious Disease Clinics of North America, 2013
- Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infectionsPublished by Wiley ,2011
- Procalcitonin as a Biomarker in Respiratory Tract InfectionClinical Infectious Diseases, 2011
- Diagnostic Tests for Agents of Community-Acquired PneumoniaClinical Infectious Diseases, 2011
- Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP – Results from the German competence network CAPNETZRespiratory Research, 2009
- The Etiology of Community‐Acquired Pneumonia in Australia: Why Penicillin plus Doxycycline or a Macrolide Is the Most Appropriate TherapyClinical Infectious Diseases, 2008
- Human Coronavirus Infections in Rural Thailand: A Comprehensive Study Using Real‐Time Reverse‐Transcription Polymerase Chain Reaction AssaysThe Journal of Infectious Diseases, 2007
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2007
- Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial StewardshipClinical Infectious Diseases, 2007
- Evaluation of a Rapid Immunochromatographic Test for Detection of Streptococcus pneumoniae Antigen in Urine Samples from Adults with Community-Acquired PneumoniaJournal of Clinical Microbiology, 2001